EQUITY RESEARCH - COMPANY REPORT

BANGKOK CHAIN HOSPITAL THAILAND / HEALTH CARE SERVICES

A small drag from fewer Kuwaiti patients

- Expect 1Q24 core profit to grow by 22% y-y to THB310m, led by solid Thai patient revenue.
- 1H24 earnings would have a mild impact from Kuwait's government policy to cut payment guarantees.
- Maintain BUY, with a lower DCF-TP of THB25.0/shr.

Expect 1Q24 revenue to grow by 8% y-y

We expect 1Q24 revenue to grow by 8% y-y. Cash patient revenue should increase by 7-8% y-y, driven by solid Thai patient revenue. However, international patient revenue should decline y-y, pressured by a slowdown in Kuwaiti patient revenue (accounting for c.30-35% of international patient revenue and 5-6% of total revenue in 2023) following Kuwait's government policy to cut payment guarantees for citizens seeking treatment overseas. SSO revenue should grow by 10% y-y, led by higher revenue per head. SSO registered members should increase by 1% y-y, given that higher members at main hospitals (KH Bangkae and KH Prachachuen) would offset lower members at KV Pathumthani, which is under renovation (scheduled completion by Jan-25). We expect the EBITDA margin to improve to 24% (vs 23% in 1Q23), leading core profit to grow by 22% y-y to THB310m.

Setup a new JV to provide mobile dental services

BCH recently set up Bangkok Chain Dental, a JV company between BCH (holding 60%) and Dental Factory (a group of dentists), to provide mobile dental services starting from 3Q24. It plans to have up to seven dental buses (2-3 dental chairs per bus). BCH will prepare and arrange customers (especially SSO) for the JV. We roughly estimate it would lift BCH revenue by c1-2% by 2025.

Kuwaiti patient revenue should pick up in 2H24

The impact of decreased Kuwaiti patient revenue should improve in 3Q24 as BCH is in talks with the Kuwait Embassy to bring hospitals under BCH back to the payment guarantees list. Currently, we expect international patient revenue to grow by 2% in 2024 (from 10% previously). Overall, we forecast 2024 revenue to grow by 8% and core profit to jump by 25% to THB1.8b on a lower FX loss from KIH Vientiane, lower revenue reversal related to Covid treatments, and a lower loss from the three new hospitals.

Trim core profit to reflect a slowdown in Kuwaiti patients

We have decreased our 2024-26E core profit by 2-6% to reflect lower international patient revenue and derive a new 2024 DCF-TP of THB25.0/shr. BCH is trading at 30x 2024E P/E, higher than its 5-year average of 27x.



Teerapol Udomvej, CFA Fundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969




BCH TB

UNCHANGED

TARGET PRICE	THB25.00
CLOSE	THB21.40
UP/DOWNSIDE	+16.8%
PRIOR TP	THB26.00
CHANGE IN TP	-3.8%
TP vs CONSENSUS	-0.5%

KEY STOCK DATA

YE Dec (THB m)	2023	2024E	2025E	2026E
	2023	20276	ZUZUL	ZUZUL
Revenue	11,729	12,647	13,803	15,069
Net profit	1,406	1,756	2,027	2,333
EPS (THB)	0.56	0.70	0.81	0.94
vs Consensus (%)	-	(1.8)	(1.9)	2.6
EBITDA	2,802	3,263	3,661	4,102
Recurring net profit	1,406	1,756	2,027	2,333
Core EPS (THB)	0.56	0.70	0.81	0.94
Chg. In EPS est. (%)	-	(5.6)	(3.6)	(2.2)
EPS growth (%)	(53.7)	24.9	15.4	15.1
Core P/E (x)	37.9	30.4	26.3	22.9
Dividend yield (%)	2.3	1.6	1.8	2.1
EV/EBITDA (x)	19.2	16.2	14.1	12.3
Price/book (x)	4.2	4.0	3.7	3.4
Net debt/Equity (%)	(4.4)	(11.3)	(18.2)	(24.8)
ROE (%)	11.2	13.5	14.5	15.4



Sources: Bloomberg consensus; FSSIA estimates

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

Investment thesis

BCH is a leading service provider under the Social Security Office (SSO) scheme, with a 7% market share. In 2024, BCH received a large SSO quota of 314k. This should lead to more registered members numbering around 40-80k for BCH this year.

In 2020-21, BCH opened three new hospitals, which continue to share a loss. However, their operations are improving, and all should turn profitable by 2025-26, leading to a better EBITDA and an improved NPM.

Revenue from international patients has already exceeded the pre-Covid level, driven by Middle Eastern and CLMV patients. BCH targets a higher revenue contribution from international patients, expecting it to rise from 17% in 2023 to 20% in 2024. This should improve the overall margin due to a higher billing size when compared to Thai patients.

Company profile

The company operates as a group, providing healthcare services for cash patients and patients under the social security scheme.

www.bangkokchainhospital.com

Principal activities (revenue, 2023)

- Cash patient revenue 68.0 %
- SSO patient revenue 32.8 %
- NHSO patient revenue (0.8) %

Source: Bangkok Chain Hospital

Major shareholders

- Chalerm Harnphanich 32.6 %
- Thai NVDR 10.0 %
- Somporn Harnphanich 6.8 %
- Others 50.6 %

Source: Bangkok Chain Hospital

Catalysts

Key potential growth drivers include 1) more SSO-registered members; 2) increased demand from medical tourists; and 3) an improved EBITDA margin led by new hospitals.

Risks to our call

Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests, or floods; 2) regulatory risks, such as controls on drug prices and medical bills; and 3) SSO provision expenses following a limited SSO budget.

Event calendar

 Date
 Event

 May 2024
 1Q24 results announcement

Key assumptions

	2024E	2025E	2026E
	(%)	(%)	(%)
SSO volume growth	4	7	7
SSO revenue / patient growth	5	3	3
OPD volume growth	4	4	4
OPD revenue / patient growth	5	3	3
IPD volume growth	4	4	4
IPD revenue / patient growth	5	3	3

Source: FSSIA estimates

Earnings sensitivity

- For every 1% increase in patient volume, we project 2024 earnings would rise by 2%, and vice versa, all else being equal.
- For every 1% increase in EBITDA margin, we project 2024 earnings would rise by 5%, and vice versa, all else being equal.

Source: FSSIA estimates




Exhibit 1: BCH - 1Q24 results preview

	1Q23	2Q23	3Q23	4Q23	1Q24E	Cha	nge	2023	2024E	Chg
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(у-у %				
Sales	2,674	2,849	3,175	3,032	2,894	(5)	8	11,729	12,647	ä
COGS (incl. depreciation)	(1,936)	(1,989)	(2,098)	(2,094)	(2,046)	(2)	6	(8,116)	(8,545)	1
Gross profit	738	860	1,077	938	848	(10)	15	3,613	4,102	14
SG&A	(398)	(495)	(470)	(392)	(430)	10	8	(1,755)	(1,821)	4
Operating profit	340	365	607	547	418	(23)	23	1,859	2,280	23
Net other income	25	28	26	40	26	(36)	5	119	120	÷
Interest expense	(28)	(24)	(30)	(13)	(13)	0	(53)	(95)	(53)	(45
Pretax profit	337	369	602	574	431	(25)	28	1,882	2,348	2
Income Tax	(70)	(86)	(135)	(114)	(86)	(24)	23	(405)	(470)	1
Associates	(1)	2	0	(0)	0			1	1	n/a
Minority interest	(12)	(1)	(27)	(32)	(35)	8	184	(73)	(123)	7
Core profit	254	284	441	427	310	(27)	22	1,406	1,756	2
Extraordinaries, GW & FX	0	0	0	0	0					
Reported net profit	254	284	441	427	310	(27)	22	1,406	1,756	2
Outstanding shares (m)	2,494	2,494	2,494	2,494	2,494	0	0	2,494	2,494	
Core EPS (THB)	0.10	0.11	0.18	0.17	0.12	(27)	22	0.56	0.70	2
EPS (THB)	0.10	0.11	0.18	0.17	0.12	(27)	22	0.56	0.70	2
COGS (excl. depreciation)	1,698	1,755	1,861	1,858	1,808	(3)	7	7,172	7,563	
Depreciation	238	234	237	236	238	1	0	944	982	
EBITDA	603	627	869	823	682	39	457	2,922	3,383	1
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(pp
Gross margin	28	30	34	31	29	(2)	2	31	32	
SG&A/Revenue	15	17	15	13	15	2	(0)	15	14	(1
EBITDA margin	23	22	27	27	24	(4)	1	24	26	
Net profit margin	9	10	14	14	11	(3)	1	12	14	

Operating stats	(y-y %)	(y-y %)	(y-y %)	(y-y %)
Cash-OPD revenue growth	(51)	(21)	(22)	8
Cash-OPD volume growth	(74)	(47)	(23)	10
Cash-OPD revenue per head growth	66	49	1	0
Cash-IPD revenue growth	(20)	13	4	9
Cash-IPD volume growth	(77)	(56)	51	23
Cash-IPD revenue per head growth	7	25	(10)	(5)
SSO revenue growth	14	16	15	12
SSO registered member ('000)	1,013	1,012	1,011	1,014
SSO registered member growth	8	4	2	0
SSO revenue per head growth	(43)	(64)	(19)	7


Sources: BCH; FSSIA estimates

Exhibit 2: Non-Covid general patient revenue



Sources: BCH; FSSIA estimates


Exhibit 3: SSO revenue, quarterly




Sources: BCH; FSSIA estimates




Exhibit 4: EBITDA margin





Note: 3Q22 excludes Moderna write-off Sources: BCH; FSSIA estimates

Exhibit 6: 2024E core profit growth breakdown



Note: Applied 20% tax for each item Source: FSSIA estimates

Exhibit 7: 2024 key earnings growth assumptions

Key growth items	Assumptions
Absence of FX loss	BCH booked a THB151m FX loss from KIH Vientiane following the LAK's depreciation against the THB in 2023. We believe the FX loss will significantly reduce to only THB30-40m in 2024 as it has repaid the THB term loan.
Absence of provision expenses	BCH booked provision expenses and a revenue reversal related to Covid treatments totaling THB121m in 2023. We expect a provision expense to reduce to THB40-50m in 2024.
Turnaround of new hospitals	Expect three new hospital losses (excluding FX loss) to narrow from THB140m-150m in 2023 to THB60-70m in 2024.
Additional SSO members	Expect registered members to increase by 25-30k in 2024 with average revenue per head of THB3,800 and an EBITDA margin of 35-40% for additional SSO revenue.
Organic growth	Expect core profit growth of 6-8%, driven by higher revenue intensity.


Source: FSSIA estimates

Sources: BCH; FSSIA estimates

Exhibit 5: Core profit



Exhibit 8: Thai general patient revenue



Sources: BCH; FSSIA estimates



Exhibit 10: SSO revenue, yearly


Sources: BCH; FSSIA estimate

Exhibit 12: Forecast revisions

		- Current			Previous			% Change			
	2024E	2025E	2026E	2024E	2025E	2026E	2024E	2025E	2026E		
SSO registered members ('000)	1,038	1,121	1,210	1,053	1,126	1,205	(1.4)	(0.5)	0.4		
SSO revenue per head (THB)	3,992	4,112	4,236	3,992	4,112	4,236	0.0	0.0	0.0		
Cash-OPD visits per day (no.)	3,133	3,258	3,389	3,133	3,258	3,389	0.0	0.0	0.0		
Cash-OPD revenue per head (THB)	3,845	3,961	4,080	3,845	3,961	4,080	0.0	0.0	0.0		
Cash-IPD admissions per day (no.)	136	142	147	136	142	147	0.0	0.0	0.0		
Cash-IPD revenue per head (THB)	82,599	86,729	91,066	86,729	89,331	92,011	(4.8)	(2.9)	(1.0)		
Revenue (THB m)	12,647	13,803	15,069	12,912	13,961	15,098	(2.1)	(1.1)	(0.2)		
EBITDA margin (%)	25.8	26.5	27.2	26.3	26.9	27.6	(0.5)	(0.4)	(0.4)		
Core profit (THB m)	1,756	2,027	2,333	1,861	2,104	2,386	(5.6)	(3.6)	(2.2)		


Note: Change of items in percentage terms are represented in ppt change Source: FSSIA estimates

Exhibit 9: International patient revenue



Sources: BCH; FSSIA estimates

Exhibit 11: EBITDA margin



Sources: BCH; FSSIA estimate

Exhibit 13: DCF-derived TP

Cost of equity assumptions	(%)	Cost of debt assumptions	(%)
Risk-free rate	3.0	Pre-tax cost of debt	4.0
Market risk premium	8.0	Marginal tax rate	20.0
Stock beta	1.0		
Cost of equity, Ke	10.6	Net cost of debt, Kd	3.2
Weight applied	70.0	Weight applied	30.0
WACC	8.4		


DCF valuation estimate	(THB b)	(THB/share)	Comments
NPV	22.1	8.9	WACC 8.4%, Risk-free rate 3%, Risk premium 8%
Terminal value	39.8	15.9	Terminal growth 3%
Cash & liquid assets	3.0	1.2	At end-2024E
Investments	0.0	0.0	At end-2024E
Debt	(1.4)	(0.6)	At end-2024E
Minorities	(1.2)	(0.5)	At end-2024E
Residual ordinary equity	62.4	25.0	

Source: FSSIA estimates





Exhibit 15: Historical P/BV band



Sources: Bloomberg; FSSIA estimates

Exhibit 16: Peer comparisons as of 26 Apr 2024

Company	BBG	Rec	\$	Share price	e	Market	Pl	E	RC)E	PE	3V	- EV/ EB	ITDA -
			Current	Target	Upside	Сар	24E	25E	24E	25E	24E	25E	24E	25E
			(LCY)	(LCY)	(%)	(USD m)	(x)	(x)	(%)	(%)	(x)	(x)	(x)	(x)
Thailand														
Bangkok Dusit Med Service	BDMS TB	BUY	29.00	35.00	20.7	12,469	28.1	25.7	16.8	17.3	4.6	4.3	17.0	15.5
Bumrungrad Hospital	BH TB	BUY	248.00	305.00	23.0	5,334	26.7	25.1	28.8	26.8	7.1	6.4	17.8	16.5
Bangkok Chain Hospital	BCH TB	BUY	21.40	25.00	16.8	1,444	30.4	26.3	13.5	14.5	4.0	3.7	16.2	14.1
Chularat Hospital	CHG TB	BUY	2.86	3.90	36.4	851	24.2	21.1	16.7	17.7	3.9	3.6	14.1	12.4
Praram 9 Hospital	PR9 TB	BUY	19.20	24.00	25.0	408	23.0	21.0	12.4	12.6	2.7	2.6	11.5	10.3
Thonburi Healthcare Group	THG TB	HOLD	40.25	44.00	9.3	923	41.9	35.0	7.8	9.1	3.2	3.1	18.3	16.5
Ramkhamhaeng Hospital	RAM TB	BUY	32.00	46.00	43.8	1,039	21.9	19.0	9.3	10.2	2.0	1.9	26.6	21.2
Rajthanee Hospital	RJH TB	n/a	25.00	n/a	n/a	206	18.0	18.5	19.1	18.8	5.1	3.3	13.3	12.5
Ekachai Medical Care	EKH TB	n/a	7.75	n/a	n/a	148	19.3	19.0	14.6	13.3	5.7	2.6	10.5	9.8
Thailand average						22,822	25.9	23.4	15.4	15.6	4.3	3.5	16.1	14.3
Regional														
Ramsay Health Care	RHC AU	n/a	52.50	n/a	n/a	7,914	35.4	39.1	8.6	7.1	2.9	2.9	11.6	10.9
Ihh Healthcare Bhd	IHH SP	n/a	1.79	n/a	n/a	11,658	34.9	31.7	6.3	5.9	2.4	2.0	14.6	13.8
Ryman Healthcare	RYM NZ	n/a	4.26	n/a	n/a	1,747	8.5	10.7	7.5	7.0	1.0	0.6	11.5	18.4
Apollo Hospitals Enterprise	APHS IN	n/a	6,259	n/a	n/a	10,293	102.1	92.5	13.8	14.1	23.6	13.4	42.1	37.3
Kpj Healthcare Berhad	KPJ MK	n/a	1.97	n/a	n/a	1,829	37.7	29.9	10.2	11.6	4.5	3.7	15.7	14.2
Raffles Medical Group	RFMD SP	n/a	1.01	n/a	n/a	1,377	21.0	25.9	8.6	7.1	2.2	1.8	10.4	12.2
Mitra Keluarga Karyasehat	MIKA IJ	n/a	2,850	n/a	n/a	2,549	42.9	37.3	17.1	18.2	8.5	7.0	26.2	23.5
Aier Eye Hospital Group	300015 CH	n/a	13.12	n/a	n/a	16,889	34.7	28.7	18.3	19.3	14.0	6.0	20.7	17.4
Regional average						54,257	39.7	37.0	11.3	11.3	7.4	4.7	19.1	18.4
Overall average						77,079	32.4	29.8	13.5	13.6	5.7	4.0	17.5	16.3

Sources: Bloomberg; FSSIA estimates

Financial Statements

Bangkok Chain Hospital

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	18,827	11,729	12,647	13,803	15,069
Cost of goods sold	(12,772)	(8,116)	(8,545)	(9,219)	(9,965)
Gross profit	6,055	3,613	4,102	4,584	5,104
Other operating income	-	-	-	-	-
Operating costs	(1,946)	(1,755)	(1,821)	(1,957)	(2,092)
Operating EBITDA	5,059	2,802	3,263	3,661	4,102
Depreciation	(950)	(944)	(982)	(1,034)	(1,090)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	4,109	1,859	2,280	2,627	3,012
Net financing costs	(148)	(77)	(37)	(34)	(26)
Associates	0	1	1	1	1
Recurring non-operating income	84	102	106	111	117
Non-recurring items	0	0	0	0	0
Profit before tax	4,046	1,883	2,349	2,704	3,103
Тах	(888)	(405)	(470)	(541)	(620)
Profit after tax	3,157	1,479	1,879	2,163	2,483
Minority interests	(118)	(73)	(123)	(136)	(150)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	3,039	1,406	1,756	2,027	2,333
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	3,039	1,406	1,756	2,027	2,333
Per share (THB)					
Recurring EPS *	1.22	0.56	0.70	0.81	0.94
Reported EPS	1.22	0.56	0.70	0.81	0.94
DPS	1.40	0.50	0.35	0.39	0.45
Diluted shares (used to calculate per share data)	2,494	2,494	2,494	2,494	2,494
Growth					
Revenue (%)	(12.0)	(37.7)	7.8	9.1	9.2
Operating EBITDA (%)	(50.6)	(44.6)	16.4	12.2	12.1
Operating EBIT (%)	(56.2)	(54.8)	22.7	15.2	14.7
Recurring EPS (%)	(55.6)	(53.7)	24.9	15.4	15.1
Reported EPS (%)	(55.6)	(53.7)	24.9	15.4	15.1
Operating performance					
Gross margin inc. depreciation (%)	32.2	30.8	32.4	33.2	33.9
Gross margin exc. depreciation (%)	37.2	38.9	40.2	40.7	41.1
Operating EBITDA margin (%)	26.9	23.9	25.8	26.5	27.2
Operating EBIT margin (%)	21.8	15.8	18.0	19.0	20.0
Net margin (%)	16.1	12.0	13.9	14.7	15.5
Effective tax rate (%)	22.0	21.5	20.0	20.0	20.0
Dividend payout on recurring profit (%)	114.9	88.7	49.7	47.6	47.8
nterest cover (X)	28.4	25.4	63.7	80.1	121.5
nventory days	12.3	17.0	15.2	15.0	15.0
Debtor days	49.3	37.0	24.2	22.2	20.3
Creditor days	41.0	67.9	67.8	67.0	66.9
Operating ROIC (%)	21.4	10.9	14.5	16.8	19.4
ROIC (%)	21.0	10.9	14.4	16.7	19.2
ROE (%)	23.9	11.2	13.5	14.5	15.4
ROA (%)	14.2	8.2	10.5	11.4	12.1
* Pre-exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Cash patient revenue	9,372	7,976	8,504	9,195	9,943
SSO patient revenue	3,371	3,850	4,142	4,608	5,126
	6,084	(97)	0	0	C

Sources: Bangkok Chain Hospital; FSSIA estimates

Financial Statements

Bangkok Chain Hospital

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
ecurring net profit	3,039	1,406	1,756	2,027	2,333
epreciation	950	944	982	1,034	1,090
ssociates & minorities	-	-	-	-	
ther non-cash items	24	114	117	136	150
hange in working capital	1,459	1,563	9	31	35
ash flow from operations	5,471	4,027	2,865	3,228	3,608
apex - maintenance	(984)	(896)	(879)	(966)	(1,055
apex - new investment	-	-	-	-	
let acquisitions & disposals	2	4	0	0	(
Other investments (net) Cash flow from investing	(982)	(892)	(879)	(966)	(1,055
Dividends paid	(3,491)	(1,247)	(873)	(966)	(1,115
quity finance	(3,491)	(1,247)	(873)	(900)	(1,115)
Debt finance	(3,153)	(2,310)	(200)	0	(
Other financing cash flows	(462)	(32)	(68)	(75)	(82
Cash flow from financing	(7,106)	(3,590)	(1,141)	(1,041)	(1,197
lon-recurring cash flows	-	-	-	-	(1,101)
Other adjustments	0	0	0	0	C
let other adjustments	0	0	0	0	Ċ
lovement in cash	(2,616)	(455)	845	1,221	1,356
ree cash flow to firm (FCFF)	4,645.31	3,230.18	2,038.56	2,317.13	2,608.09
ree cash flow to equity (FCFE)	875.07	791.94	1,718.22	2,187.08	2,470.54
er share (THB)					
CFF per share	1.86	1.30	0.82	0.93	1.05
FCFE per share	0.35	0.32	0.69	0.88	0.99
Recurring cash flow per share	1.61	0.99	1.14	1.28	1.43
talance Sheet (THR m) Year Ending Dee			2024E	20255	20205
Balance Sheet (THB m) Year Ending Dec	2022	2023		2025E	2026E
angible fixed assets (gross)	20,274	20,884	21,769	22,735	23,790
ess: Accumulated depreciation	(7,992)	(8,639)	(9,622)	(10,655)	(11,745
angible fixed assets (net)	12,282	12,244	12,147	12,080	12,045
ntangible fixed assets (net)	425	440	440	440	440
ong-term financial assets	-	-	-	-	
nvest. in associates & subsidiaries	32	28	28	28	28
Cash & equivalents	2,640	2,185	3,031	4,252	5,607
VC receivable	1,539	839	839	839	839
nventories	362	306	322	349	378
Dther current assets Current assets	2,294 6,835	1,513 4,843	1,631 5,823	1,780 7,220	1,943 8,76 8
Dther assets	223	4,843 176	176	176	176
fotal assets	19,796	17,731	18,614	19,943	21,457
Common equity	12,445	12,594	13,477	14,539	15,757
Ainorities etc.	1,065	1,110	1,166	1,227	1,295
fotal shareholders' equity	13,510	13,704	14,643	15,766	17,051
ong term debt	3,888	1,497	1,297	1,297	1,297
Other long-term liabilities	163	187	187	187	187
.ong-term liabilities	4,051	1,684	1,484	1,484	1,484
VC payable	1,300	1,368	1,442	1,561	1,693
Short term debt	0	81	81	81	81
Other current liabilities	935	894	964	1,052	1,148
Current liabilities	2,235	2,342	2,487	2,694	2,922
otal liabilities and shareholders' equity	19,796	17,731	18,614	19,943	21,457
let working capital	1,959	396	387	356	320
nvested capital	14,921	13,284	13,178	13,079	13,009
Includes convertibles and preferred stock which is bei					
er share (THB)					
look value per share	4.99	5.05	5.40	5.83	6.32
angible book value per share	4.82	4.87	5.23	5.65	6.14
inancial strength					
let debt/equity (%)	9.2	(4.4)	(11.3)	(18.2)	(24.8
let debt/total assets (%)	6.3	(3.4)	(8.9)	(14.4)	(19.7)
Current ratio (x)	3.1	(3.4)	2.3	2.7	(19.7
CF interest cover (x)	6.9	11.3	46.9	65.0	96.9
aluation	2022	2023	2024E	2025E	2026E
Recurring P/E (x) *	17.6	37.9	30.4	26.3	22.9
Recurring P/E @ target price (x) *	20.5	44.3	35.5	30.8	26.7
Reported P/E (x)	17.6	37.9	30.4	26.3	22.9
Dividend yield (%)	6.5	2.3	1.6	1.8	2.1
Price/book (x)	4.3	4.2	4.0	3.7	3.4
Price/tangible book (x)	4.4	4.4	4.1	3.8	3.5
V/EBITDA (x) **	11.0	19.2	16.2	14.1	12.3
V/EBITDA @ target price (x) ** V/invested capital (x)	12.8	22.4	19.0	16.6	14.5
	3.7	4.1	4.0	4.0	3.9

Sources: Bangkok Chain Hospital; FSSIA estimates



Bangkok Chain Hospital PCL (BCH TB)

FSSIA ESG rating

 $\star \star \star$

39.71 /100

Exhibit 17: FSSIA ESG score implication

Rating	Score	Implication
*****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
$\star\star\star\star$	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 18: ESG – peer comparison

	FSSIA			Domes	stic ratings	\$		Global ratings						Bloomberg		
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score	
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17	
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94	
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60	
BDMS	74.00	Y	Y	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92	
BH	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79	
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24	
PR9	54.08		Y	Y	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90	
PRINC	18.00				4.00	4.00	Certified									
RAM	11.75				3.00			High								
THG	18.75				5.00	5.00		High								
VIBHA	20.88				4.00	3.00	Declared	High					17.00			

Sources: <u>SETTRADE.com</u>; FSSIA's compilation

Exhibit 19: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	0.56	0.71	0.75	0.72	0.80	0.85	2.36	3.52
BESG environmental pillar score	0.00	0.00	0.00	0.00	0.38	0.38	2.96	4.63
BESG social pillar score	0.00	0.22	0.22	0.22	0.22	0.22	1.70	3.47
BESG governance pillar score	2.35	2.41	2.62	2.50	2.41	2.63	3.19	2.91
ESG disclosure score	18.06	19.81	19.81	19.81	20.08	20.08	31.27	47.60
Environmental disclosure score	0.00	0.42	0.42	0.42	1.24	1.24	20.57	46.18
Social disclosure score	3.17	10.52	10.52	10.52	10.52	10.52	18.53	41.96
Governance disclosure score	50.87	48.37	48.37	48.37	48.37	48.37	54.64	54.64
Environmental								
Emissions reduction initiatives	No	No	No	No	Yes	Yes	Yes	Yes
Climate change policy	No	No	No	No	No	No	Yes	Yes
Climate change opportunities discussed	No							
Risks of climate change discussed	No							
GHG scope 1	_	—	—	—	—	_	1	2
GHG scope 2 location-based	_	—	—	—	—	_	5	6
GHG Scope 3	_	—	—	—	—	_	—	_
Carbon per unit of production	_	_	_	_	_	_	—	_
Biodiversity policy	No							
Energy efficiency policy	No	Yes						
Total energy consumption	—	_	_	_	_	_	10	12
Renewable energy use	_	_	_	_	_	_	_	_
Electricity used	_	_	_	_	_	_	10	12
Fuel used - natural gas	_	_	_	_	_	_	_	_

Sources: Bloomberg; FSSIA's compilation

Exhibit 20: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No							
Waste reduction policy	No	No	No	No	Yes	Yes	Yes	Yes
Hazardous waste	—	—	—	—	—	—	—	0
Total waste	—	_	—	—	—	_	_	0
Waste recycled	—	_	—	—	—	_	_	0
Waste sent to landfills		_	_			_		0
Environmental supply chain management	No	Yes						
Water policy	No	No	No	No	No	No	Yes	Yes
Water consumption	_	—	_	_	_	_	_	-
Social								
Human rights policy	No	Yes						
Policy against child labor	No	Yes						
Quality assurance and recall policy	No	Yes						
Consumer data protection policy	No							
Equal opportunity policy	Yes							
Gender pay gap breakout	No							
Pct women in workforce	—	—	—	—	—	—	—	76
Pct disabled in workforce	—	—	—	—	—	—	—	1
Business ethics policy	Yes							
Anti-bribery ethics policy	No	Yes						
Health and safety policy	No	Yes						
Lost time incident rate - employees	_	—	_	—	_	_	0	0
Total recordable incident rate - employees	—	_	_	—	—	_	0	1
Training policy	No	Yes						
Fair remuneration policy	No	Yes						
Number of employees – CSR	—	—	_	—	—	_	8,597	8,877
Employee turnover pct	—	—	—	—	—	—	—	43
Total hours spent by firm - employee training	—	—	_	—	—	_	—	54,702
Social supply chain management	No	Yes						
Governance								
Board size	10	10	10	12	12	12	12	11
No. of independent directors (ID)	4	4	4	4	4	4	4	4
No. of women on board	3	3	3	4	4	3	3	3
No. of non-executive directors on board	5	5	5	5	5	5	5	5
Company conducts board evaluations	Yes							
No. of board meetings for the year	6	5	6	5	5	6	6	6
Board meeting attendance pct	93	94	90	96	100	99	94	97
Board duration (years)	—	—	—	—	—	—	—	_
Director share ownership guidelines	No							
Age of the youngest director	28	29	30	29	30	31	32	33
Age of the oldest director	72	73	74	75	76	77	78	79
No. of executives / company managers	5	5	5	5	5	7	7	6
No. of female executives	1	_	_	_	_	_	_	_
Executive share ownership guidelines	No							
Size of audit committee	3	3	3	3	3	3	3	3
No. of ID on audit committee	3	3	3	3	3	3	3	3
Audit committee meetings	4	4	5	5	5	5	5	5
Audit meeting attendance %	100	92	100	93	100	100	93	100
Size of compensation committee	0	0	0	0	0	0	0	0
No. of ID on compensation committee	_	_		_	_			_
No. of compensation committee meetings	_	_	_	_	_	_	_	_
Compensation meeting attendance %	_	_	_	_	_	_	_	_
Size of nomination committee	0	0	0	0	0	0	0	0
No. of nomination committee meetings	_	_	_	_	_	_	_	_
Nomination meeting attendance %	_	_	_	_	_	_	_	_
-								
Sustainability governance								

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodolog	У			Rating							
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process base from the ann Only the top- inclusion.	ed on the com ual S&P Glob ranked comp	transparent, rules-based npanies' Total Sustainabi nal Corporate Sustainabil anies within each industr	lity Scores resulting ity Assessment (CSA). y are selected for	Be a member and invited to the annual S&P Global Corporate Sustainability Assessment (CSA) for DJSI. Companies with an S&P Global ESG Score of less than 45% of the S&P Global ESG Score of the highest scoring company are disqualified. The constituents of the DJSI indices are selected from the Eligible Universe.							
Sustainability Investment List (<u>THSI</u>) by The Stock Exchange of Thailand (<u>SET</u>)	managing bu Candidates n 1) no irregula float of >150 up capital. So 70%; 2) indep wrongdoing r	siness with tr nust pass the ar trading of th shareholders ome key disq pendent direc related to CG	ility in Environmental and ansparency in Governan e preemptive criteria, with ne board members and e s, and combined holding i ualifying criteria include: ctors and free float violati , social & environmental earnings in red for > 3 yes	ace, updated annually. two crucial conditions: executives; and 2) free must be >15% of paid- 1) CG score of below on; 3) executives' impacts; 4) equity in	To be eligible for <u>THSI inclusion</u> , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against the nature of the relevant industry and materiality. <u>SETTHSI Index</u> is extended from the THSI companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight a maximum, and no cap for number of stocks.							
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by t	he Thai IOD, T). The resul	h in sustainable develop with support from the St ts are from the perspecti s.	ock Exchange of	Good (80-89), 3 and not rated for equitable treatm	6 for Good (70 or scores below ment of shareh 5%); 4) disclo	ories: 5 for Excell -79), 2 for Fair (6 v 50. Weightings olders (weight 25 sure & transpare	0-69), 1 for P include: 1) th 5% combined	ass (60-69), e rights; 2) and ; 3) the role of			
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment are transparent a out of five the criteria cover date (45%), a circulation of su exercised. The and verifiability.	e incorporated and sufficientl e CG compor AGM proced and after the i ufficient information second assess c; and 3) openne	which shareholders' right: d into business operation y disclosed. All form imp- ients to be evaluated anr dures before the meeting meeting (10%). (The first a tion for voting; and 2) facilita ses 1) the ease of attending in sess for Q&A. The third involve less, resolutions and voting re	s and information is ortant elements of two nually. The assessment (45%), at the meeting ssesses 1) advance ting how voting rights can be neetings; 2) transparency as the meeting minutes that	The scores are classified into four categories: 5 for Excellent (100), 4 for Very Good (90-99), 3 for Fair (80-89), and not rated for scores below 79.							
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishmen policies. The (Companies de Declaration of I Certification, in managers and	nt of key contr Certification eciding to becom Intent to kick officiuding risk ass employees, est	Checklist include corrupti rols, and the monitoring a is good for three years. In a CAC certified member s f an 18-month deadline to sui sessment, in place of policy a tablishment of whistleblowing II stakeholders.)	and developing of start by submitting a bmit the CAC Checklist for nd control, training of	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.							
<u>Morningstar</u> <u>Sustainalytics</u>	based on an risk is unman regulatory filing	assessment naged. Source as, news and ot	isk rating provides an ove of how much of a compa s to be reviewed include corp her media, NGO reports/web	ny's exposure to ESG porate publications and sites, multi-sector	A company's ESG risk rating score is the sum of unmanaged risk. The more risk is unmanaged, the higher ESG risk is scored. NEGL Low Medium High Severe							
	reports, and qu		k, ESG controversies, issuer iews.	feedback on draft ESG	0-10	10-20	20-30	30-40	40+			
ESG Book	positioned to the principle helps explain	outperform o of financial m future risk-a ng features w	sustainable companies th over the long term. The m lateriality including inform djusted performance. Ma ith higher materiality and arly basis.	nethodology considers nation that significantly nteriality is applied by	The total ESG score is calculated as a weighted sum of the features scores using materiality-based weights. The score is scaled between 0 and 100 with higher scores indicating better performance.							
<u>MSCI</u>				anagement of financially their exposure to ESG ris					ethodology to			
	AAA AA	8.571-10.00 7.143-8.57(Leader:	leading its industry in m	anaging the most si	gnificant ESG ris	sks and opportunitie	S				
	A BBB BB	BBB 4.286-5.713 Average: a mixed or unexceptional track record of managing the most significant ESG risks and opportunities rela industry peers										
	 B 1.429-2.856 CCC 0.000-1.428 Laggard: lagging its industry based on its high exposure and failure to manage significant ESG risks 											
<u>Moody's ESG</u> solutions	believes that	esses the dec a company in	gree to which companies	take into account ESG o to its business model and medium to long term.								
<u>Refinitiv ESG</u> rating	based on put	blicly availabl	e and auditable data. The	e a company's relative ES e score ranges from 0 to are 0 to 25 = poor; >25 to 50	100 on relative E	SG performan	ce and insufficier	nt degree of tr				
S&P Global				asuring a company's perf ssification. The score ran			of ESG risks, opp	oortunities, an	d impacts			
	compared to its peers within the same industry classification. The score ranges from 0 to 100. ESG Score Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean)											
Bloomberg	ESG Score		score is based on Bloo		incial materiality.	The score is a	a weighted gener	alized mean (power mean)			

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings. Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

Company	Ticker	Price	Rating	Valuation & Risks
Bangkok Chain Hospital	BCH TB	THB 21.40	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following a limited SSO budget.
Bangkok Dusit Medical Services	BDMS TB	THB 29.00	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher-than-expected capex and opex for CoE projects.
Bumrungrad Hospital	ВН ТВ	THB 248.00	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher medical fee discount promotions, leading to a weaker EBITDA margin.
Chularat Hospital	CHG TB	THB 2.86	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.
Praram 9 Hospital	PR9 TB	THB 19.20	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.
Thonburi Healthcare Group	THG TB	THB 40.25	HOLD	Upside risks to our DCF-based target price include 1) a new Covid wave from a new variant; and 2) big-lot sales of Jin Wellbeing County units. Downside risks include 1) regulatory risks from drug prices and medical bill controls; and 2) a slowdown in international patients due to economic concerns.
Ramkhamhaeng Hospital	RAM TB	THB 32.00	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) losses from its subsidiary companies.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 26-Apr-2024 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months. **Neutral.** The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months. **Underweight.** The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.